Business
Jazz Pharmaceuticals to Present Advancements in Sleep Medicine at Psych Congress 2022
Seven abstracts emphasize Jazz's leadership in neuroscience and commitment to ongoing innovation DUBLIN, Sept. 15, 2022 /PRNewswire/ -- Jazz Pharmaceuticals
About this update from Jazz Pharmaceuticals Plc
[{"type":"text","content":"Seven abstracts emphasize Jazz's leadership in neuroscience and commitment to ongoing innovation\nDUBLIN, Sept. 15, 2022 /PRNewswire/ -- Jazz Pharmaceuticals plc (Nasdaq: JAZZ) today announced that the Company will present seven abstracts from across its neuroscience portfolio at the 35th annual Psych Congress 2022, being held September 17-20, 2022.\n\"Our presence at Psych Congress 2022 further reinforces Jazz's position as a pioneer in sleep medicine and therapies,\" said Kelvin Tan, MB BCh, MRCPCH, senior vice president and chief medical officer of Jazz Pharmaceuticals. \"Jazz has long been at the forefront of providing therapies and support for our patients living with serious, debilitating sleep disorders, having launched the only U.S. Food and Drug Administration (FDA)-approved lower-sodium oxybate for the treatment of cataplexy or excessive daytime sleepiness in patients 7 years of age and older with narcolepsy and the only FDA-approved treatment for adults with idiopathic hypersomnia. We look forward to presenting these data at the meeting, as they provide another significant opportunity to share this important research with the greater sleep medicine community.\"\nHighlights at Psych Congress 2022 include:\nNew results from a post hoc analysis evaluating the efficacy of Xywav® (calcium, magnesium, potassium, and sodium oxybates) oral solution in the open-label treatment phase of a study in idiopathic hypersomnia.Encore interim data from both the TENOR and SEGUE studies in narcolepsy patients transitioning from sodium oxybate to lower-sodium Xywav.The Psych Congress 2022 presentations are available on-demand through the conference mobile application. A list of poster presentations follows below:\nPresentation Title\nLeadAuthor\nDate / Time (CT) / SessionTitle / Presentation Number\nNarcolepsy Data\nDosing and Reasons for Transitioning From Sodium Oxybate to Lower-Sodium Oxybate in People With Narcolepsy: Data From the Real-World TENOR Study\nAM Husain\nType: Poster\nPoster number: 170\nSession dates/times: September 18, 2022 from 1:30-3:00PM; September 19, 2022 from 1:30-3:00PM\nEffectiveness and Treatment Optimization Among Participants With Narcolepsy Switching From Sodium Oxybate to Lower-Sodium Oxybate: Interim Data From the SEGUE Study\nEB Leary\nType: Poster\nPoster number: 156\nSession dates/times: September 18, 2...